Cyprotex Ltd-医療機器分野:企業M&A・提携分析

◆英語タイトル:Cyprotex Ltd - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013865
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cyprotex Ltd (Cyprotex), a subsidiary of Evotec AG is a provider of ADME-Tox contract research services. It provides these services to the biotechnology, pharmaceutical, cosmetics/personal care and chemical industries. The company’s core capabilities include high quality mechanistic toxicology, in vitro ADME screening services, and high content toxicology screening services, including proprietary CellCiphr toxicity prediction technology, predictive modelling using QSAR and PBPK techniques, including Cloe PK for in vivo PK prediction, and a range of endocrine and skin, ocular disruption services. Cyprotex partners with various organizations within the cosmetics and personal care industry, biotech and pharmaceutical industry, and the chemical industry. The company’s operations are primarily carried out in the UK and the US. Cyprotex is headquartered in Nether Alderley, Cheshire, the UK.

Cyprotex Ltd – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cyprotex Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cyprotex Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cyprotex Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cyprotex Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cyprotex Ltd, Medical Equipment, Deal Details 10
Partnerships 10
Cyprotex Enters Into Agreement With InSphero For New 3D Microtissue Service 10
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 11
Acquisition 12
Evotec Acquires Cyprotex for USD68 Million 12
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 14
Cyprotex Ltd – Key Competitors 15
Cyprotex Ltd – Key Employees 16
Cyprotex Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Jan 26, 2017: Cyprotex, an Evotec Company, Expands into New UK Facility at Alderley Park 18
Financial Announcements 19
Aug 02, 2016: Cyprotex: Interim Results 2016 19
Apr 01, 2016: Cyprotex Announces Final results for the year ended 31 December 2015 22
Corporate Communications 23
Sep 26, 2016: Cyprotex: Cyprotex appoint new Director of US Operations 23
Sep 26, 2016: Cyprotex appoint new Director of US Operations 24
Product News 25
Nov 29, 2016: Cyprotex: Launch of in vitro h-CLAT Service for assessing skin sensitisation 25
Oct 06, 2016: Cyprotex: New DDI-Fusion Combines Chemical Structure with In Vitro Data to Predict Human Drug-Drug Interactions 26
Jul 07, 2016: Cyprotex Announces Launch of New Advanced 3D Cardiotoxicity Model 27
Jun 23, 2016: Cyprotex Launch New Endocrine Disruption Service 28
Other Significant Developments 29
Jun 09, 2016: Cyprotex Purchase New IntelliCyt iQue Screener for Expansion of Cell-Based Services 29
Apr 26, 2016: Launch of GLP-Compliant Genotoxicity Services 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Cyprotex Ltd, Medical Equipment, Key Facts, 2016 2
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Cyprotex Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cyprotex Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cyprotex Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cyprotex Ltd, Deals By Market, 2011 to YTD 2017 8
Cyprotex Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cyprotex Enters Into Agreement With InSphero For New 3D Microtissue Service 10
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 11
Evotec Acquires Cyprotex for USD68 Million 12
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 14
Cyprotex Ltd, Key Competitors 15
Cyprotex Ltd, Key Employees 16
Cyprotex Ltd, Subsidiaries 17

★海外企業調査レポート[Cyprotex Ltd-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alere Toxicology Plc:企業の戦略的SWOT分析
    Alere Toxicology Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Centers for Disease Control and Prevention-製薬・医療分野:企業M&A・提携分析
    Summary Centers for Disease Control and Prevention (CDC), a subsidiary of US Department of Health and Human Services is a public health institute that offers health, safety and security threat management solutions. The institute provides health information to fight diseases and support communities f …
  • Verastem Inc (VSTM):企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Orchard Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Orchard Therapeutics Ltd (Orchard) is an integrated commercial-stage biotechnology company that develops gene therapies for the treatment of serious and life-threatening orphan diseases. Its pipeline products include Strimvelis, an autologous ex vivo gammaretroviral gene therapy for the trea …
  • Senhwa Biosciences Inc (6492):製薬・医療:M&Aディール及び事業提携情報
    Summary Senhwa Biosciences Inc (Senhwa) is a clinical stage drug development company that develops next generation DNA damage response drugs for the treatment of cancer. The company’s pipeline products include CX-5461 and CX-4945. Its CX-5461, a G4-stabilizing compound, is a Pol I inhibitor that tri …
  • Retail Food Group Limited (Foodservice):企業の戦略・SWOT・財務分析
    Retail Food Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Retail Food Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • United Rentals Inc:企業の戦略・SWOT・財務情報
    United Rentals Inc - Strategy, SWOT and Corporate Finance Report Summary United Rentals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Glythera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Glythera Ltd (Glythera) is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprie …
  • Mallinckrodt, LLC-製薬・医療分野:企業M&A・提携分析
    Summary Mallinckrodt LLC (Mallinckrodt), a subsidiary of Mallinckrodt Plc is a biophramaceutical company that develops medicines. The company manufactures, markets and distributes generic and specialty pharmaceuticals, active pharmaceutical ingredients, diagnostic imaging agents, global medical imag …
  • Constellation Pharmaceuticals Inc (CNST):企業の財務・戦略的SWOT分析
    Constellation Pharmaceuticals Inc (CNST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Madrigal Pharmaceuticals Inc (MDGL):企業の財務・戦略的SWOT分析
    Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • China Shineway Pharmaceutical Group Ltd (2877):企業の財務・戦略的SWOT分析
    Summary China Shineway Pharmaceutical Group Ltd (China Shineway) is a pharmaceutical company that offers development, manufacture and sales of Chinese medicines. The company’s products comprise shenmai injection, qingkailing injection, huangqi injection, shuxiening injection, wufu xinnaoqing soft ca …
  • Seven Bank, Ltd.:企業の戦略・SWOT・財務情報
    Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Program for Appropriate Technology in Health-製薬・医療分野:企業M&A・提携分析
    Summary Program for Appropriate Technology in Health (PATH) is a healthcare organization that offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. The organization offers HIV and AIDS, influenza, malaria and tuberculosis care services. It develo …
  • Petropavlovsk PLC:企業の戦略・SWOT・財務情報
    Petropavlovsk PLC - Strategy, SWOT and Corporate Finance Report Summary Petropavlovsk PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Galilee Energy Ltd (GLL):企業の財務・戦略的SWOT分析
    Summary Galilee Energy Ltd (Galilee) is a mining and minerals exploration and development company that offer exploration and development services. The company acquires, explores, produces, and develops coal seam gas in the Galilee Basin near Longreach in Queensland. It offers projects such as ATP799 …
  • FirstEnergy Corp (FE):電力:M&Aディール及び事業提携情報
    Summary FirstEnergy Corp. (FirstEnergy) is a diversified energy company, which generates, transmits, distributes and sells electricity. The company’s regulated distribution companies form one of the nation's largest investor-owned electric systems. Its major electricity generating assets include coa …
  • Expedia Inc:企業のM&A・事業提携・投資動向
    Expedia Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Expedia Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • AltaGas Ltd.:企業の戦略・SWOT・財務情報
    AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report Summary AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆